Detalhe da pesquisa
1.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Blood
; 143(8): 673-684, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37883795
2.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662991
3.
Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
Br J Haematol
; 204(3): 910-920, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38098188
4.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469514
5.
Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
Br J Haematol
; 202(4): 760-770, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052611
6.
Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
Eur J Haematol
; 110(2): 168-176, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36321745
7.
Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell Lymphoma.
Curr Treat Options Oncol
; 24(8): 929-947, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37249800
8.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244251
9.
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.
Eur J Haematol
; 108(6): 469-485, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35158410
10.
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments.
Nature
; 538(7626): 518-522, 2016 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-27750279
11.
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
Br J Haematol
; 195(1): 113-118, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34426978
12.
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
N Engl J Med
; 378(13): 1211-1223, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29590547
13.
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
Br J Haematol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38544472
14.
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Blood
; 129(25): 3362-3370, 2017 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-28473407
15.
Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
Blood
; 129(12): 1685-1690, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28126926
16.
Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Eur J Nucl Med Mol Imaging
; 46(9): 1902-1910, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31187162
17.
A novel ATRX variant with splicing consequences in myelodysplastic syndrome with acquired alpha thalassaemia.
Br J Haematol
; 200(1): e13-e16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36278851
18.
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Br J Haematol
; 202(4): 893-896, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280781
19.
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Blood
; 127(25): 3215-24, 2016 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-27069256
20.
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.
Blood
; 125(1): 71-81, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25336628